Wall Street brokerages predict that Nektar Therapeutics (NASDAQ:NKTR) will post sales of $114.14 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $134.47 million and the lowest is $71.40 million. Nektar Therapeutics reported sales of $36.34 million in the same quarter last year, which would indicate a positive year over year growth rate of 214.1%. The firm is expected to report its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $114.14 million for the current financial year, with estimates ranging from $219.00 million to $314.20 million. For the next year, analysts anticipate that the firm will report sales of $199.03 million per share, with estimates ranging from $152.89 million to $282.15 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) EPS.

Several research analysts have recently issued reports on NKTR shares. Aegis restated a “buy” rating and issued a $27.00 target price on shares of Nektar Therapeutics in a report on Wednesday, May 10th. Jefferies Group LLC cut their target price on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Roth Capital set a $31.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Thursday, May 11th. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $26.10.

Nektar Therapeutics (NKTR) opened at 21.03 on Friday. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The stock has a 50 day moving average of $20.23 and a 200-day moving average of $18.96. The firm’s market cap is $3.29 billion.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/01/114-14-million-in-sales-expected-for-nektar-therapeutics-nktr-this-quarter.html.

In related news, CEO Howard W. Robin sold 91,714 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.26, for a total value of $1,766,411.64. Following the completion of the sale, the chief executive officer now owns 152,504 shares of the company’s stock, valued at $2,937,227.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Ivan P. Gergel sold 54,920 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total value of $1,158,812.00. Following the completion of the sale, the senior vice president now directly owns 98,492 shares of the company’s stock, valued at approximately $2,078,181.20. The disclosure for this sale can be found here. Insiders sold 237,629 shares of company stock valued at $4,820,217 in the last ninety days. 6.10% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the company. Flinton Capital Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the last quarter. LS Investment Advisors LLC raised its stake in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the last quarter. Meadow Creek Investment Management LLC raised its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 616 shares during the last quarter. Finally, Riverhead Capital Management LLC raised its stake in shares of Nektar Therapeutics by 78.7% in the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 3,854 shares during the last quarter. 95.11% of the stock is owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.